Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection

Virology

Volumn 312, Issue 2, 2003, Pages 415-424

  Mahanty, Siddhartha ^a,d,e   Gupta, Manisha ^a,b   Paragas, Jason ^c   Bray, Mike ^c,d   Ahmed, Rafi ^b   Rollin, Pierre E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cytokines; Ebola virus; Filovirus; Innate immunity; Interferons; Pathogenesis; Protective immunity; Viral kinetics

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; MONOCYTE CHEMOTACTIC PROTEIN 1; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD LEVEL; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; EBOLA VIRUS; FEMALE; IMMUNE RESPONSE; INFLAMMATION; KIDNEY; LETHALITY; LIVER; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SPLEEN; TISSUE LEVEL; VIRUS INFECTION; VIRUS REPLICATION;

EBOLA VIRUS; MARBURG-LIKE VIRUSES;

EID: 0043166564     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00233-2     Document Type: Article

References (46)

1. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull. World Health Organ. 56:(2):1978;247-270.
2. Ebola haemorrhagic fever in Zaire, 1976. Bull. World Health Organ. 56:(2):1978;271-293.
3. Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. MMWR Morb. Mortal Wkly. Rep. 50:(5):2001;73-77.
4. Baize S., Leroy E.M., Georges-Courbot M.C., Capron M., Lansoud-Soukate J., Debre P., Fisher-Hoch S.P., McCormick J.B., Georges A.J. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5:(4):1999;423-426.
5. Baize S., Leroy E.M., Mavoungou E., Fisher-Hoch S.P. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis. 5:(1):2000;5-7.
6. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:2000;767-811.
7. Baron R.C., McCormick J.B., Zubeir O.A. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull. World Health Organ. 61:(6):1983;997-1003.
8. Basler C.F., Wang X., Muhlberger E., Volchkov V., Paragas J., Klenk H.D., Garcia-Sastre A., Palese P. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. USA. 97:(22):2000;12289-12294.
9. Biron C.A. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10:(5):1998;383-390.
10. Biron C.A. Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr. Opin. Microbiol. 2:(4):1999;374-381.
11. Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82:(Pt. 6):2001;1365-1373.
12. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:(3):1998;651-661. [published erratum appears in J Infect. Dis., 178(5), 1553 (1998)].
13. Bray M., Raymond J.L., Geisbert T., Baker R.O. 3-Deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res. 55:(1):2002;151-159.
14. Cousens L.P., Peterson R., Hsu S., Dorner A., Altman J.D., Ahmed R., Biron C.A. Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J. Exp. Med. 189:(8):1999;1315-1328.
15. Feldmann H., Volchkov V.E., Volchkova V.A., Klenk H.D. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch. Virol. Suppl. 15:1999;159-169.
16. Geisbert T.W., Hensley L.E., Gibb T.R., Steele K.E., Jaax N.K., Jahrling P.B. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80:(2):2000;171-186.
17. Gibb T.R., Bray M., Geisbert T.W., Steele K.E., Kell W.M., Davis K.J., Jaax N.K. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125:(4):2001;233-242.
18. Gupta M., Mahanty S., Ahmed R., Rollin P.E. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology. 284:(1):2001;20-25.
19. Gupta M., Mahanty S., Bray M., Ahmed R., Rollin P.E. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 75:(10):2001;4649-4654.
20. Harcourt B.H., Sanchez A., Offermann M.K. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology. 252:(1):1998;179-188.
21. Harcourt B.H., Sanchez A., Offermann M.K. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J. Virol. 73:(4):1999;3491-3496.
22. Hensley L.E., Young H.A., Jahrling P.B., Geisbert T.W. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80:(3):2002;169-179.
23. Hutchinson K.L., Villinger F., Miranda M.E., Ksiazek T.G., Peters C.J., Rollin P.E. Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype). J. Med. Virol. 65:(3):2001;561-566.
24. Khan A.S., Tshioko F.K., Heymann D.L., Le Guenno B., Nabeth P., Kerstiens B., Fleerackers Y., Kilmarx P.H., Rodier G.R., Nkuku O., Rollin P.E., Sanchez A., Zaki S.R., Swanepoel R., Tomori O., Nichol S.T., Peters C.J., Muyembe-Tamfum J.J., Ksiazek T.G. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J. Infect. Dis. 179:(Suppl. 1):1999;S76-S86.
25. Ksiazek T.G., Rollin P.E., Jahrling P.B., Johnson E., Dalgard D.W., Peters C.J. Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J. Clin. Microbiol. 30:(4):1992;947-950.
26. Ksiazek T.G., Rollin P.E., Williams A.J., Bressler D.S., Martin M.L., Swanepoel R., Burt F.J., Leman P.A., Khan A.S., Rowe A.K., Mukunu R., Sanchez A., Peters C.J. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179:(Suppl. 1):1999;S177-S187.
27. Ksiazek T.G., West C.P., Rollin P.E., Jahrling P.B., Peters C.J. ELISA for the detection of antibodies to Ebola viruses. J. Infect. Dis. 179:(Suppl. 1):1999;S192-S198.
28. Leroy, E.M., Baize, S., Volchkov, V.E.F., Fisher-Hoch, S.P., Georges-Courbot, M.-C., Lansoud- Soukate, J., Capron, M., Debré, P., McCormick, J.B., Georges, A.J., 2000. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355, 2210-2215.
29. Mahanty S., Kalwar R., Rollin P.E. Cytokine measurement in biological samples after physicochemical treatment for inactivation of biosafety level 4 viral agents. J. Med. Virol. 59:(3):1999;341-345.
30. Parren P.W., Geisbert T.W., Maruyama T., Jahrling P.B., Burton D.R. Pre and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76:(12):2002;6408-6412.
31. Peters C.J., LeDuc J.W. An introduction of Ebola: the virus and the disease. J. Infect. Dis. 179:(Suppl. 1):1999;ix-xvi.
32. Pulendran B., Palucka K., Banchereau J. Sensing pathogens and tuning immune responses. Science. 293:(5528):2001;253-256.
33. Rao M., Bray M., Alving C.R., Jahrling P., Matyas G.R. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J. Virol. 76:(18):2002;9176-9185.
34. Rao M., Matyas G.R., Grieder F., Anderson K., Jahrling P.B., Alving C.R. Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A. Vaccine. 17:(23-24):1999;2991-2998.
35. Sanchez A.S., Khan A.S., Zaki S.R., Nabel G.J., Ksiazek T.G., Peters C.J. Filoviridae: Marburg and Ebola viruses. Pathology and pathogenesis. Knipe D.M., Howley P.M. Field's Virology, fourth ed. Vol. 1, 2 vols. Lippincott. 2001;1293-1297 Williams and Wilkins, Philadelphia, PA.
36. Schnittler H.J., Feldmann H. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin. Infect. Dis. 27:(2):1998;404-406.
37. Schnittler H.J., Feldmann H. Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr. Topics Microbiol. Immunol. 235:1999;175-204.
38. Stroher U., West E., Bugany H., Klenk H.D., Schnittler H.J., Feldmann H. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75:(22):2001;11025-11033.
39. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 408:(6812):2000;605-609.
40. Takada A., Feldmann H., Stroeher U., Bray M., Watanabe S., Ito H., McGregor M., Kawaoka Y. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 77:(2):2003;1069-1074.
41. Villinger F., Rollin P.E., Brar S.S., Chikkala N.F., Winter J., Sundstrom J.B., Zaki S.R., Swanepoel R., Ansari A.A., Peters C.J. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179:(Suppl. 1):1999;S188-S191.
42. Wilson J.A., Bray M., Bakken R., Hart M.K. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology. 286:(2):2001;384-390.
43. Wilson J.A., Hart M.K. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol. 75:(6):2001;2660-2664.
44. Wilson J.A., Hevey M., Bakken R., Guest S., Bray M., Schmaljohn A.L., Hart M.K. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 287:(5458):2000;1664-1666.
45. Xu L., Sanchez A., Yang Z., Zaki S.R., Nabel E.G., Nichol S.T., Nabel G.J. Immunization for Ebola virus infection. Nat. Med. 4:(1):1998;37-42.
46. Zaki S.R., Goldsmith C.S. Pathologic features of filovirus infections in humans. Curr. Top. Microbiol. Immunol. 235:1999;97-116.